肥胖干预措施的长期成本效果:一项孟德尔随机化研究
该研究利用英国生物银行310,913名39至72岁白种英国人的数据,采用孟德尔随机化方法估计BMI对质量调整生命年和医疗费用的因果效应。结果显示BMI每增加1单位,每年QALY下降0.65%,总医疗费用增加42.23英镑;腹腔镜减重手术和高脂高盐高糖食品促销限制均具有成本效果。
要点
- BMI每增加1单位,年QALY下降0.65%,年总医疗费用增加42.23英镑。
- 仅考虑常见合并症时,BMI对QALY的影响被低估(仅0.16%)。
- 腹腔镜减重手术(BMI>35)和限制不健康食品促销均具成本效果。
核心结论
- 孟德尔随机化可用于估计干预对生活质量和医疗费用的影响。
- 考虑240种慢性病时,BMI对健康相关生活质量的影响远大于仅考虑有限疾病。
- 既往成本效果研究可能低估了BMI对生活质量的影响及减重干预的潜在成本效果。
研究设计与样本
- 研究基于英国生物银行310,913名39至72岁白种英国人的数据,随访至2017年3月31日。
- 使用孟德尔随机化,以BMI多基因风险评分作为工具变量,调整年龄、性别、招募中心和40个遗传主成分。
- 通过模拟估计政策相关干预对BMI的影响,并结合孟德尔随机化估计进行成本效果分析。
主要发现
- BMI每增加1单位,每年QALY下降0.65%(95%CI:0.49%至0.81%)。
- BMI每增加1单位,每人每年总医疗费用增加42.23英镑(95%CI:32.95至51.51)。
- 仅考虑癌症、心血管疾病、脑血管疾病和2型糖尿病时,BMI每增加1单位每年QALY仅下降0.16%(95%CI:0.10%至0.22%)。
- BMI>35 kg/m2者行腹腔镜减重手术,20年内每人净货币收益为13,936英镑(95%CI:8,112至20,658)(按每QALY 20,000英镑计算)。
关键数值与推荐
- BMI每增加1单位,年QALY下降0.65%(95%CI:0.49%至0.81%),年总医疗费用增加42.23英镑(95%CI:32.95至51.51)。
- 仅考虑癌症、心血管疾病、脑血管疾病和2型糖尿病时,BMI每增加1单位年QALY下降0.16%(95%CI:0.10%至0.22%)。
- BMI>35 kg/m2者行腹腔镜减重手术,20年净货币收益为13,936英镑(95%CI:8,112至20,658)(按每QALY 20,000英镑计算)。
临床怎么用
- 孟德尔随机化可用于估计肥胖干预的长期成本效果。
- 评估减重干预时需考虑BMI对多种慢性病生活质量的综合影响。
- 腹腔镜减重手术和限制不健康食品促销可能具有成本效果。
局限性
- 孟德尔随机化依赖无法证明的假设,包括无方向性多效性和基因型与混杂因素独立。
- 研究仅纳入白种英国人,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevalence of obesity has increased in the United Kingdom, and reliably measuring the impact on quality of life and the total healthcare cost from obesity is key to informing the cost-effectiveness of interventions that target obesity, and determining healthcare funding. Current methods for estimating cost-effectiveness of interventions for obesity may be subject to confounding and reverse causation. The aim of this study is to apply a new approach using mendelian randomisation for estimating the cost-effectiveness of interventions that target body mass index (BMI), which may be less affected by confounding and reverse causation than previous approaches. METHODS AND FINDINGS: We estimated health-related quality-adjusted life years (QALYs) and both primary and secondary healthcare costs for 310,913 men and women of white British ancestry aged between 39 and 72 years in UK Biobank between recruitment (2006 to 2010) and 31 March 2017. We then estimated the causal effect of differences in BMI on QALYs and total healthcare costs using mendelian randomisation. For this, we used instrumental variable regression with a polygenic risk score (PRS) for BMI, derived using a genome-wide association study (GWAS) of BMI, with age, sex, recruitment centre, and 40 genetic principal components as covariables to estimate the effect of a unit increase in BMI on QALYs and total healthcare costs. Finally, we used simulations to estimate the likely effect on BMI of policy relevant interventions for BMI, then used the mendelian randomisation estimates to estimate the cost-effectiveness of these interventions. A unit increase in BMI decreased QALYs by 0.65% of a QALY (95% confidence interval [CI]: 0.49% to 0.81%) per year and increased annual total healthcare costs by £42.23 (95% CI: £32.95 to £51.51) per person. When considering only health conditions usually considered in previous cost-effectiveness modelling studies (cancer, cardiovascular disease, cerebrovascular disease, and type 2 diabetes), we estimated that a unit increase in BMI decreased QALYs by only 0.16% of a QALY (95% CI: 0.10% to 0.22%) per year. We estimated that both laparoscopic bariatric surgery among individuals with BMI greater than 35 kg/m2, and restricting volume promotions for high fat, salt, and sugar products, would increase QALYs and decrease total healthcare costs, with net monetary benefits (at £20,000 per QALY) of £13,936 (95% CI: £8,112 to £20,658) per person over 20 years, and £546 million (95% CI: £435 million to £671 million) in total per year, respectively. The main limitations of this approach are that mendelian randomisation relies on assumptions that cannot be proven, including the absence of directional pleiotropy, and that genotypes are independent of confounders. CONCLUSIONS: Mendelian randomisation can be used to estimate the impact of interventions on quality of life and healthcare costs. We observed that the effect of increasing BMI on health-related quality of life is much larger when accounting for 240 chronic health conditions, compared with only a limited selection. This means that previous cost-effectiveness studies have likely underestimated the effect of BMI on quality of life and, therefore, the potential cost-effectiveness of interventions to reduce BMI.
引用
- Harrison S, Dixon P, Jones HE, et al. Long-term cost-effectiveness of interventions for obesity: A mendelian randomisation study. PLoS Med. 2021. PMID: 34449774. doi:10.1371/journal.pmed.1003725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。